Merit Medical Systems Bolsa (NASDAQ: MMSI)

Últimas noticias sobre Merit Medical Systems (NASDAQ:MMSI) Bolsa

MERIT MEDICAL SYSTEMS INC

Merit Medical Systems

Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems Inc

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) has outperformed the market over the past 20 years by 1.28% on an annualized basis producing an average annual return of 9.54%. Currently, Merit Medical Systems has a market capitalization of $5.58 billion. 
Buying $1000 In MMSI: If an investor had bought $1000 of MMSI stock 20 years ago, it would be worth $6,363.21 today based on a price of $94.43 for MMSI at the time of writing.
<h3>Merit Medical Systems's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748465111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

MMSI

Here's How Much $1000 Invested In Merit Medical Systems 20 Years Ago Would Be Worth Today

Piper Sandler analyst Jason Bednar maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and raises the price target from $106 to $110.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Merit Medical Systems, Raises Price Target to $110

Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $108 to $112.

Canaccord Genuity Maintains Buy on Merit Medical Systems, Raises Price Target to $112

Wells Fargo analyst Larry Biegelsen maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Overweight and raises the price target from $106 to $108.

Wells Fargo Maintains Overweight on Merit Medical Systems, Raises Price Target to $108

Needham analyst Mike Matson reiterates Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and maintains $108 price target.

Reiteration

Needham Reiterates Buy on Merit Medical Systems, Maintains $108 Price Target

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) lowers FY2025 Adj EPS guidance from $3.29-$3.42 to $3.28-$3.41 vs $3.65 analyst estimate. Raises FY2025 sales outlook from $1.47 billion-$1.49 billion to $1.48 billion-$1.50 billion vs $1.48 billion estimate.

Guidance

Merit Medical Systems Lowers FY2025 Adj EPS Guidance from $3.29-$3.42 to $3.28-$3.41 vs $3.65 Est; Raises FY2025 Sales Guidance from $1.47B-$1.49B to $1.48B-$1.50B vs $1.48B Est

Merit's updated full-year 2025 financial guidance now reflects the projected impacts of the Biolife acquisition from the merger effective date of May 20, 2025 through December 31, 2025. Merit is otherwise reaffirming prior full-year 2025 financial guidance previously announced on April 24, 2025.

Merit Medical Systems Now Sees FY25 Net Sales Of $1.480B - $1.501B Vs Prior Guidance Range Of $1.470B - $1.490B; Now Expects FY25 Non-GAAP EPS Of $3.28-$3.41 Vs Prior Outlook Of $3.29-$3.42

<ul>
<li>Acquired business offers the StatSeal&#xAE; and WoundSeal&#xAE; products, which provide hemostasis solutions that complement the wide range of procedures Merit's portfolio supports.</li>
<li>Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile</li>
<li>Merit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acquisition</li>
</ul>
Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. ("Biolife") in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal.
The aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately $120 million. This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance.

Merit Medical Systems Acquires Biolife Delaware In $120M Merger Transaction

Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 13.27%. Currently, Merit Medical Systems has a market capitalization of $5.84 billion. 
Buying $1000 In MMSI: If an investor had bought $1000 of MMSI stock 15 years ago, it would be worth $6,432.79 today based on a price of $98.83 for MMSI at the time of writing.
<h3>Merit Medical Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747666815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Merit Medical Systems Stock In The Last 15 Years

In the preceding three months, 14 analysts have released ratings for Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Merit Medical Systems, presenting an average target of $111.93, a high estimate of $127.00, and a low estimate of $100.00. A 3.58% drop is evident in the current average compared to the previous average price target of $116.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1747335659_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$116.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$127.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$116.00</td>
<td>$122.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Merit Medical Systems's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Merit Medical Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Unveiling the Story Behind Merit Medical Systems</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>A Deep Dive into Merit Medical Systems's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 9.84%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.48%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.15%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Merit Medical Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Merit Medical Systems In The Eyes Of 14 Experts

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and raises the price target from $100 to $108.

Needham Maintains Buy on Merit Medical Systems, Raises Price Target to $108

<ul>
<li>The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.</li>
<li>Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial.</li>
</ul>
SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval from Health Canada. With this approval, Merit intends to begin immediate commercialization of the device throughout Canada with devices shipped from Merit's Toronto distribution center.

Merit Medical Systems Receives Health Canada Regulatory Approval For Wrapsody Cell-Impermeable Endoprosthesis

Biotech

General

Merit Medical Releases 12-Month Efficacy Results For Single-Arm Arteriovenous Graft Cohort Of WRAPSODY Arteriovenous Efficacy Trial

Throughout the last three months, 17 analysts have evaluated Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate of $128.00, and a low estimate of $100.00. Observing a downward trend, the current average is 2.51% lower than the prior average price target of $117.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618451_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$127.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $108.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $103.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$116.00 &#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $110.00&#x7C;$111.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $112.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $111.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $116.00&#x7C;$116.00 &#x7C; 
&#x7C;Robbie Marcus &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $120.00&#x7C;- &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $111.00&#x7C;$115.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$128.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $117.00&#x7C;$120.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $116.00&#x7C;$122.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $116.00&#x7C;$114.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$114.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $128.00&#x7C;$127.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $122.00&#x7C;$109.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Merit Medical Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Merit Medical Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of 7.87%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 2.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Merit Medical Systems In The Eyes Of 17 Experts

Canaccord Genuity analyst Jon Young maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $127 to $108.

Canaccord Genuity Maintains Buy on Merit Medical Systems, Lowers Price Target to $108

Raymond James analyst Jayson Bedford maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $116 to $108.

Raymond James Maintains Outperform on Merit Medical Systems, Lowers Price Target to $108

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $111 to $103.

Barrington Research Maintains Outperform on Merit Medical Systems, Lowers Price Target to $103

Needham analyst Mike Matson maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Buy and lowers the price target from $116 to $100.

Needham Maintains Buy on Merit Medical Systems, Lowers Price Target to $100

Baird analyst David Rescott maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $111 to $110.

Baird Maintains Outperform on Merit Medical Systems, Lowers Price Target to $110

WIIM

MMSI stock has given up its prior loss. Merit Medical Systems shares were trading lower after the company cut its FY25 adjusted EPS guidance.

Press Releases

First Patient Enrolled in Merit Medical's PREEMIE Study

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Health Care

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

Updated ASGE Clinical Practice Guideline Includes TIF 2.0 and cTIF for Management of GERD

Merit Medical Systems to Announce First Quarter 2025 Results on April 24, 2025

Merit Medical Launches the Ventrax™ Delivery System

Earnings

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

Comments

Merit Medical Systems

Noticias

Últimas noticias sobre Merit Medical Systems (NASDAQ:MMSI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL